glp 1 drugs and autoimmune disease The anti-inflammatory immunological properties of GLP-1 Receptor Agonists GLP-1 Obesity Drugs May Lower
Description
Some of the inconsistency across preclinical reports reflects differences in the compounds, doses, and assay conditions used, so standardised reporting of peptide characterisation and experimental conditions would make the literature easier to interpret and to replicate
Current studies are still largely in the preclinical or early clinical phases, and larger trials involving human subjects are necessary to confirm the safety and efficacy of these drugs for addiction treatment
Back Mller, TD, Blher, M, Tschp, M, DiMarchi, iRD (2022) 'Anti-obesity drug discovery: advances and challenges', Nature Review Drug Discovery , 21, 201-23
Limited insurance coverage and recent shortages only complicate access
L.BanerjiM
These pleiotropic effects include the reduction of BW and BP, the improvement of lipid metabolism and a spectrum of cardioprotective effects
